ReviewACS synthetic biology2015
Opportunities for synthetic biology in antibiotics: expanding glycopeptide chemical diversity.
Review in ACS synthetic biology, 2015. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 20 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
20 citing papers in PubMed.
- Complete Genome Assembly ofGenes · 2024Article
- Mixture design of α-pinene, α-terpineol, and 1,8-cineole: A multiobjective response followed by chemometric approaches to optimize the antibacterial effect against various bacteria and antioxidant activity.Food science & nutrition · 2024Article
- Resourcefulness of propylprodigiosin isolated from Brevundimonas olei strain RUN-D1.AMB Express · 2023Article
- Heterologous Expression Reveals Ancient Properties of Tei3—A VanS Ortholog from the Teicoplanin Producer Actinoplanes teichomyceticusInternational journal of molecular sciences · 2022Article
- Occurrence ofGenes · 2022Article
- Mapping and Exploiting the Promiscuity of OxyB toward the Biocatalytic Production of Vancomycin Aglycone Variants.ACS catalysis · 2020Article
- Biological, chemical, and biochemical strategies for modifying glycopeptide antibiotics.The Journal of biological chemistry · 2019Review
- Drug Resistance and the Prevention Strategies in Food Borne Bacteria: An Update Review.Advanced pharmaceutical bulletin · 2019Review
- Engineering modular intracellular protein sensor-actuator devices.Nature communications · 2018Article
- Applications of Nonenzymatic Catalysts to the Alteration of Natural Products.Chemical reviews · 2017Review
- Sulfation and amidinohydrolysis in the biosynthesis of giant linear polyenes.Beilstein journal of organic chemistry · 2017Article
- Engineering microbial hosts for production of bacterial natural products.Natural product reports · 2016Review
- Harnessing natural product assembly lines: structure, promiscuity, and engineering.Journal of industrial microbiology & biotechnology · 2016Review
- Endless Resistance. Endless Antibiotics?MedChemComm · 2016Article
- Reinvigorating natural product combinatorial biosynthesis with synthetic biology.Nature chemical biology · 2015Article
- Structure diversification of vancomycin through peptide-catalyzed, site-selective lipidation: a catalysis-based approach to combat glycopeptide-resistant pathogens.Journal of medicinal chemistry · 2015Article
- Synthetic biology for pharmaceutical drug discovery.Drug design, development and therapy · 2015Review
- Old and New Glycopeptide Antibiotics: Action and Resistance.Antibiotics (Basel, Switzerland) · 2014Review
- Antibiotic resistance-mediated isolation of scaffold-specific natural product producers.Nature protocols · 2014Article
- Identifying producers of antibacterial compounds by screening for antibiotic resistance.Nature biotechnology · 2013Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
2 authors.
Funding
Abstract
Synthetic biology offers a new path for the exploitation and improvement of natural products to address the growing crisis in antibiotic resistance. All antibiotics in clinical use are facing eventual obsolesce as a result of the evolution and dissemination of resistance mechanisms, yet there are few new drug leads forthcoming from the pharmaceutical sector. Natural products of microbial origin have proven over the past 70 years to be the wellspring of antimicrobial drugs. Harnessing synthetic biology thinking and strategies can provide new molecules and expand chemical diversity of known antibiotic scaffolds to provide much needed new drug leads. The glycopeptide antibiotics offer paradigmatic scaffolds suitable for such an approach. We review these strategies here using the glycopeptides as an example and demonstrate how synthetic biology can expand antibiotic chemical diversity to help address the growing resistance crisis.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.